Evidence map›Paper›PMID 40534661›Full record

ArticleACS pharmacology & translational science2025

Multi-Target Glitazones for Modulating Peroxisome Proliferator-Activated Receptor-γ, Cyclooxygenase-2, and Carbonic Anhydrases for the Management of Metabolic Dysfunction.

Perihan A Elzahhar, Hisham A Nematalla, Malak A Abouayana, El Sayed H El Ashry, Mahmoud Balbaa, Andrea Petreni, Rasha Nassra, Hend A Yassin, Yasmine N Kamel, Mohamed A Elrewiny and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Perihan A ElzahharDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.ORCID https://orcid.org/0000-0003-2665-6019
Hisham A NematallaDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Damanhour University, Damanhour 22516, Egypt.
Malak A AbouayanaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
El Sayed H El AshryChemistry Department, Faculty of Science, Alexandria University, Alexandria 21568, Egypt.ORCID https://orcid.org/0000-0001-5480-239X
Mahmoud BalbaaBiochemistry Department, Faculty of Science, Alexandria University, Alexandria 21568, Egypt.
Andrea PetreniNeurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FIorence, Italy.
Rasha NassraDepartment of Medical Biochemistry, Faculty of Medicine, Alexandria University, Alexandria 21131, Egypt.
Hend A YassinDepartment of Medical Biochemistry, Faculty of Medicine, Alexandria University, Alexandria 21131, Egypt.
Yasmine N KamelDepartment of Medical Biochemistry, Faculty of Medicine, Alexandria University, Alexandria 21131, Egypt.
Mohamed A ElrewinyFaculty of Pharmacy and the Research & Innovation Hub, Alamein International University, Alamein 51718, Egypt.
Mahmoud A AgamiFaculty of Pharmacy and the Research & Innovation Hub, Alamein International University, Alamein 51718, Egypt.ORCID https://orcid.org/0000-0003-0854-2819
Monica MakkarFaculty of Pharmacy and the Research & Innovation Hub, Alamein International University, Alamein 51718, Egypt.
Minh SaiDepartment of Pharmacy, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.ORCID https://orcid.org/0009-0004-6053-9566
Daniel MerkDepartment of Pharmacy, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.ORCID https://orcid.org/0000-0002-5359-8128
Hala F LabibDepartment of Pharmaceutical Chemistry, College of Pharmacy, Arab Academy of Science Technology and Maritime Transport, Alamein 21913, Egypt.
Rosaria SpagnuoloDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, via Belmeloro 6, 40126 Bologna, Italy.
Marina NaldiDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, via Belmeloro 6, 40126 Bologna, Italy.
Manuela BartoliniDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, via Belmeloro 6, 40126 Bologna, Italy.ORCID https://orcid.org/0000-0002-2890-3856
Soad A El-HawashDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
Claudiu T SupuranNeurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FIorence, Italy.ORCID https://orcid.org/0000-0003-4262-0323
Ahmed S F BelalDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.ORCID https://orcid.org/0000-0001-9463-0844
Ahmed F El-YazbiFaculty of Pharmacy and the Research & Innovation Hub, Alamein International University, Alamein 51718, Egypt.ORCID https://orcid.org/0000-0003-3432-3038

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In light of the significant correlation between inflammatory alterations and metabolic dysfunction throughout different stages of metabolic disease progression, we focused on utilizing our previously characterized glitazone-derived anti-inflammatory 1,2,3-triazoles as lead compounds to create new multitarget directed ligands that interact with COX-2, peroxisome proliferator-activated receptor γ (PPARγ), and CA within the framework of metabolic disorders. Notably, seven compounds exhibited equivalent or similar COX-2 inhibitory effects to celecoxib. Four compounds, namely,

Indexed as

carbonic anhydrasesCOX-2diabetesinflammationmultitarget directed ligandsPPARγ

Identifiers

PMID40534661
PMCPMC12171889

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.